Published in:
01-08-2010 | Editorial
A new tool for detection of type I interferon activation in systemic lupus erythematosus
Authors:
Kyriakos A Kirou, George D Kalliolias
Published in:
Arthritis Research & Therapy
|
Issue 4/2010
Login to get access
Abstract
The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-I might be important in the prognosis and activity assessment of the disease. Therefore, new biomarkers that reflect activity of the IFN-I pathway and are simple to measure, such as the monocyte CD64 receptor, are expected to have a great impact on the management of SLE, if properly validated.